產學研發徵求夥伴en文章 – 【國家衛生研究院】技轉及育成中心

Technology Available for Industry-Academia Collaboration or Technology Licensing. “Taiwan Polycystic Kidney Disease”(2023/7/10)

Uncategorized / 2023 年 7 月 11 日 2023 年 7 月 11 日

Technology Available for Industry-Academia Collaboration or Technology Licensing. “Taiwan Polycystic Kidney Disease” Date: 2023.7.10 1.Title: NHRI technology, “Taiwan Polycystic Kidney Disease” (abbreviated as“The Technology”) available for industry-academia collaboration or technology licensing. 2.Description: Autosomal Dominant polycystic kidney disease (ADPKD) is the most common inherited adult kidney disease. Although ADPKD is primarily caused by PKD1 and PKD2, …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “Taiwan Polycystic Kidney Disease”(2023/7/10) Read More »

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: A CXCR4-Targeted Antagonist” (2022/7/26)

Latest news-English, Uncategorized, 技術-EN, 產學研發-EN / 2022 年 7 月 26 日 2022 年 7 月 26 日

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: A CXCR4-Targeted Antagonist” Date: 2022.7.26 1. Title: NHRI technology, “DBPR807: A CXCR4-Targeted Antagonist” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. 2. Description: DBPR807 is a small molecule CXCR4 antagonist. DBPR807 can significantly suppress tumor growth of hepatocellular carcinoma via reducing angiogenesis, …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: A CXCR4-Targeted Antagonist” (2022/7/26) Read More »

Technology Available for Industry-Academia Collaboration or Technology Licensing. “A Potential COVID-19 Therapeutic Compound”(2020/4/16)

產學研發徵求夥伴en文章, 產學研發徵求夥伴en文章, 產學研發徵求夥伴en文章, 產學研發徵求夥伴en文章, 產學研發徵求夥伴en文章 / 2020 年 4 月 16 日 2021 年 9 月 2 日

Description The licensing technology is about a proprietary Madin-Darby canine kidney cell line (NHRI sMDCK) capable of growing in suspension culture without serum. Further disclosed are culturing methods for growing the NHRI sMDCK cell line and methods for producing a vaccine from the MDCK cell line grown in the chemically defined medium. Traditionally, cell lines, …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “A Potential COVID-19 Therapeutic Compound”(2020/4/16) Read More »

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: a CXCR4-Targeted Antagonist”(2019/07/24)

技術轉移招商en文章 / 2019 年 7 月 24 日 2021 年 9 月 2 日

Title: NHRI technology, “DBPR807: a CXCR4-Targeted Antagonist” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. Description: DBPR807 is a potent antagonist targeting CXCR4 receptors for medical treatment of peripheral blood stem cell transplantation, hepatocellular carcinoma and acute myocardial infarction. Potential collaboration partner qualifications: be incorporated and approved by law and does not …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: a CXCR4-Targeted Antagonist”(2019/07/24) Read More »

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR215: A Stem Cell Mobilizer for Cell Based Therapy”(2019/07/24)

技術轉移招商en文章, 技術轉移招商en文章, 技術轉移招商en文章 / 2019 年 7 月 24 日 2021 年 9 月 2 日

Title: NHRI technology, “DBPR215: A Stem Cell Mobilizer for Cell Based Therapy” (abbreviated as “The Technology”) available for industry-academia collaboration technology licensing. Description: DBPR807 is a potent antagonist targeting CXCR4 receptors for medical treatment of peripheral blood stem cell transplantation, hepatocellular carcinoma and acute myocardial infarction. Potential collaboration partner qualifications: be incorporated and approved by …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR215: A Stem Cell Mobilizer for Cell Based Therapy”(2019/07/24) Read More »